Related Experiment Video

Updated: Jun 1, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Risk of sudden death in end-stage hypertrophic cardiomyopathy

Hirotaka Kawarai1, Katsuya Kajimoto, Yuichiro Minami

  • 1Department of Cardiology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.

Journal of Cardiac Failure
|June 1, 2011
PubMed

Insights

End-stage hypertrophic cardiomyopathy (HCM) carries a high risk of sudden death. Syncope is a key predictor, suggesting aggressive treatment strategies are needed for these high-risk patients.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Sudden Cardiac Death Studies

Background:

  • The risk of sudden death in end-stage hypertrophic cardiomyopathy (HCM) with reduced left ventricular (LV) systolic function is not well-established.
  • Existing research often focuses on HCM patients with preserved LV function, leaving a knowledge gap for advanced disease stages.

Purpose of the Study:

  • To determine the incidence of sudden death in patients diagnosed with end-stage HCM.
  • To identify clinical factors that predict sudden death in this patient population.

Main Methods:

  • Retrospective analysis of 490 consecutive HCM patients.
  • End-stage HCM defined by LV ejection fraction <50% via echocardiography.
  • Follow-up data analyzed for sudden death events and predictors.

Main Results:

  • Out of 490 HCM patients, 43 (8.8%) progressed to end-stage HCM.
  • Among end-stage patients, 21 of 43 (47%) experienced sudden death over a mean 5-year follow-up.
  • Syncope was identified as an independent predictor of sudden death (HR=6.15, P<.001).

Conclusions:

  • End-stage HCM is associated with a significantly high rate of sudden death.
  • Aggressive therapeutic strategies should be considered to mitigate sudden death risk in end-stage HCM patients.
  • Identifying patients with syncope is crucial for risk stratification.
Abstract

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...